Table 3.
Therapeutic targeting of TNF superfamily members in cancer
| Mode of therapy | Target | Combination treatment | Tumour type |
|---|---|---|---|
| Stimulatory antibody or ligand Fc protein |
OX40 | NA | Sarcoma, melanoma, glioma, colon carcinoma, mammary carcinoma, thymoma and renal-cell carcinoma |
| Adoptive transfer of CTLs | Sarcoma, thymoma and prostate tumour | ||
| Administration of IL-12 and 4-1BB-specific antibody |
Colon carcinoma | ||
| Administration of GM-CSF | Colon and breast carcinoma | ||
| Tumour transfection with CD80 | B-cell lymphoma | ||
| Administration of DC vaccine and 4-1BB-specific antibody |
Breast carcinoma | ||
| Administration of GM-CSF and tumour antigen vaccine |
Breast tumour | ||
| Administration of IL-12 | Sarcoma and prostate tumor | ||
| 4-1BB | NA | Sarcoma, mastocytoma, glioma, colon carcinoma and B-cell lymphoma |
|
| Administration of IL-12 | Colon carcinoma and melanoma | ||
| Adoptive transfer of CTLs | Plasmacytoma | ||
| FLT3L-mediated DC mobilization | Fibrosarcoma | ||
| HLA-DR- and CD40-specific antibodies | Renal carcinoma and mammary carcinoma | ||
| 5-fluorouracil | Renal carcinoma | ||
| CD27 | NA | B-cell lymphoma | |
| Transfection of tumour cells |
OX40L | Administration of GM-CSF | Melanoma, lung carcinomathymoma and colon carcinoma |
| 4-1BBL | CD80 co-transfection | Sarcoma and colon carcinoma | |
| CD80 and CD86 co-transfection | B-cell lymphoma | ||
| IL-12 co-transfection | Colon carcinoma | ||
| CD80 | Squamous-cell carcinoma | ||
| CD80, CD40L and CD48 co-transfection | T-cell lymphoma | ||
| Adoptive transfer of LAK cells and NK cells |
Adenocarcinoma | ||
| TRANCE, CD95L and CCL21 co-transfection |
T-cell lymphoma | ||
| Soluble PD1 co-transfection | Hepatocarcinoma | ||
| Single-chain Fv fragments specific for 4-1BB |
NA | Melanoma and mammary carcinoma | |
| CD70 | NA | Sarcoma, mastocytoma, colon carcinoma, thymoma, lymphoma, mammary adenocarcinoma and glioma |
|
| CD80 co-transfection | Melanoma and mammary adenocarcinoma | ||
| CD40L co-transfection | Melanoma | ||
| Transfection of DCs | OX40L | NA | Melanoma, thymoma and melanoma |
| 4-1BBL | NA | Colon carcinoma and adenocarcinoma | |
| CD70 | NA | Thymoma | |
| Stimulatory RNA aptamer |
OX40 | Administration of DC vaccine | Melanoma |
| 4-1BB | NA | Mastocytoma | |
| Depleting antibody | CD70 | NA | B-cell lymphoma, renal carcinoma and non-Hodgkin lymphoma |
There is an online version of this table that includes references. See Supplementary information S1 (Table). 4-1BBL, 4-1BB ligand; CCL21, CC-chemokine ligand 21; CD95L, CD95 ligand; CTL, cytotoxic T lymphocyte; DC, dendritic cell; DR3, death receptor 3; FLT3, FMS-related tyrosine kinase 3; GM-CSF; granulocyte/macrophage colony-stimulating factor; IL, interleukin; LAK, lymphokine activated killer; NA, not applicable; NK, natural killer; PD1, programmed cell death 1; TNF, tumour necrosis factor; TRANCE, TNF-related activation-induced cytokine.